Verrica Pharmaceuticals (VRCA)
(Real Time Quote from BATS)
$1.80 USD
-0.01 (-0.55%)
Updated Sep 23, 2024 02:52 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Verrica Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 70 | 34 | 70 | 65 | 62 |
Receivables | 4 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 4 | 4 | 2 | 3 |
Total Current Assets | 78 | 39 | 74 | 68 | 65 |
Net Property & Equipment | 1 | 4 | 4 | 3 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 1 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 2 | 0 |
Total Assets | 82 | 45 | 80 | 74 | 68 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 1 | 0 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 42 | 35 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 14 | 3 | 3 | 3 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 1 | 0 |
Total Current Liabilities | 17 | 3 | 46 | 39 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 43 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 1 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 62 | 5 | 48 | 41 | 3 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 250 | 203 | 172 | 137 | 127 |
Retained Earnings | -230 | -163 | -139 | -104 | -61 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 20 | 40 | 33 | 33 | 65 |
Total Liabilities & Shareholder's Equity | 82 | 45 | 80 | 74 | 68 |
Total Common Equity | 20 | 40 | 33 | 33 | 65 |
Shares Outstanding | 42.00 | 41.00 | 27.50 | 25.80 | 25.70 |
Book Value Per Share | 0.47 | 0.98 | 1.19 | 1.28 | 2.53 |
Fiscal Year End for Verrica Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 32 | 49 | 70 | 84 | 55 |
Receivables | 10 | 8 | 4 | 4 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 3 | 1 | 0 | 0 |
Other Current Assets | 2 | 2 | 3 | 3 | 1 |
Total Current Assets | 47 | 61 | 78 | 92 | 57 |
Net Property & Equipment | 1 | 1 | 1 | 4 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 1 | 0 |
Total Assets | 52 | 66 | 82 | 97 | 62 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 3 | 2 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 1 | 1 | 0 | 0 | 0 |
Accrued Expenses | 18 | 16 | 14 | 9 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 20 | 19 | 17 | 11 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 43 | 43 | 43 | 42 | 0 |
Non-Current Capital Leases | 2 | 2 | 1 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 65 | 65 | 62 | 55 | 7 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 255 | 252 | 250 | 248 | 236 |
Retained Earnings | -268 | -251 | -230 | -206 | -181 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -13 | 2 | 20 | 42 | 55 |
Total Liabilities & Shareholder's Equity | 52 | 66 | 82 | 97 | 62 |
Total Common Equity | -13 | 2 | 20 | 42 | 55 |
Shares Outstanding | 42.40 | 42.40 | 42.00 | 42.00 | 41.90 |
Book Value Per Share | -0.31 | 0.04 | 0.47 | 1.01 | 1.32 |